315 related articles for article (PubMed ID: 17879989)
1. Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67.
Joguparthi V; Xiang TX; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):400-20. PubMed ID: 17879989
[TBL] [Abstract][Full Text] [Related]
2. Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH.
Joguparthi V; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):433-54. PubMed ID: 17918731
[TBL] [Abstract][Full Text] [Related]
3. Determination of intraliposomal pH and its effect on membrane partitioning and passive loading of a hydrophobic camptothecin, DB-67.
Joguparthi V; Feng S; Anderson BD
Int J Pharm; 2008 Mar; 352(1-2):17-28. PubMed ID: 18065174
[TBL] [Abstract][Full Text] [Related]
4. Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions.
Modi S; Xiang TX; Anderson BD
J Control Release; 2012 Sep; 162(2):330-9. PubMed ID: 22800581
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics simulations and experimental studies of binding and mobility of 7-tert-butyldimethylsilyl-10-hydroxycamptothecin and its 20(S)-4-aminobutyrate ester in DMPC membranes.
Xiang TX; Jiang ZQ; Song L; Anderson BD
Mol Pharm; 2006; 3(5):589-600. PubMed ID: 17009858
[TBL] [Abstract][Full Text] [Related]
6. Effect of cyclodextrin complexation on the liposome permeability of a model hydrophobic weak Acid.
Joguparthi V; Anderson BD
Pharm Res; 2008 Nov; 25(11):2505-15. PubMed ID: 18642063
[TBL] [Abstract][Full Text] [Related]
7. Modified hydrolysis kinetics of the active lactone moiety of 10-hydroxycamptothecin by liposomal encapsulation.
Shi K; Tian Y; Jiang Y; Wang L; Cui F
Pharm Dev Technol; 2010 Dec; 15(6):644-52. PubMed ID: 19943738
[TBL] [Abstract][Full Text] [Related]
8. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.
Bom D; Curran DP; Zhang J; Zimmer SG; Bevins R; Kruszewski S; Howe JN; Bingcang A; Latus LJ; Burke TG
J Control Release; 2001 Jul; 74(1-3):325-33. PubMed ID: 11489514
[TBL] [Abstract][Full Text] [Related]
9. Influence of intravesicular pH drift and membrane binding on the liposomal release of a model amine-containing permeant.
Tejwani RW; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):381-99. PubMed ID: 17694543
[TBL] [Abstract][Full Text] [Related]
10. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions.
Lundberg BB
Anticancer Drug Des; 1998 Jul; 13(5):453-61. PubMed ID: 9702210
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles.
Yang L; Cui F; Cun D; Tao A; Shi K; Lin W
Int J Pharm; 2007 Aug; 340(1-2):163-72. PubMed ID: 17482779
[TBL] [Abstract][Full Text] [Related]
12. Artificial lipids stabilized camptothecin incorporated in liposomes.
Maitani Y; Katayama S; Kawano K; Hayama A; Toma K
Biol Pharm Bull; 2008 May; 31(5):990-3. PubMed ID: 18451532
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of camptothecin into N-phthaloyl chitosan-g-mPEG self-assembly micellar system.
Opanasopit P; Ngawhirunpat T; Chaidedgumjorn A; Rojanarata T; Apirakaramwong A; Phongying S; Choochottiros C; Chirachanchai S
Eur J Pharm Biopharm; 2006 Nov; 64(3):269-76. PubMed ID: 16870407
[TBL] [Abstract][Full Text] [Related]
14. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
Atyabi F; Farkhondehfai A; Esmaeili F; Dinarvand R
Acta Pharm; 2009 Jun; 59(2):133-44. PubMed ID: 19564139
[TBL] [Abstract][Full Text] [Related]
15. Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method.
Stano P; Bufali S; Pisano C; Bucci F; Barbarino M; Santaniello M; Carminati P; Luisi PL
J Liposome Res; 2004; 14(1-2):87-109. PubMed ID: 15461935
[TBL] [Abstract][Full Text] [Related]
16. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
[TBL] [Abstract][Full Text] [Related]
17. Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution.
Flaten GE; Chang TT; Phillips WT; Brandl M; Bao A; Goins B
J Liposome Res; 2013 Mar; 23(1):70-81. PubMed ID: 23210622
[TBL] [Abstract][Full Text] [Related]
18. The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.
Fugit KD; Anderson BD
J Control Release; 2014 Jan; 174():88-97. PubMed ID: 24231406
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Lipid Composition on the Liposomal Delivery of Camptothecin Developed by Active Click Loading.
Xie L; Zhang Q; Zhu Q; Wang Y; Niu S; Zhang X; Huang Y; Li J; Liu X; Xue Z; Zhao X; Zheng Y
Mol Pharm; 2024 May; 21(5):2327-2339. PubMed ID: 38576375
[TBL] [Abstract][Full Text] [Related]
20. Investigation of parameters influencing incorporation, retention and cellular cytotoxicity in liposomal formulations of poorly soluble camptothecin.
Whitaker RD; Ingebrigtsen SG; Naderkhani E; Skar ML; Flaten GE
J Liposome Res; 2013 Dec; 23(4):298-310. PubMed ID: 23763495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
